AstraZeneca confirms that it is exploring potential strategic options with Acerta Pharma BV, a clinical-stage biopharmaceutical company based in Oss, The Netherlands. AstraZeenca did not further elaborate. “There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction,” said AstraZeneca in a statement. “The company will make a further announcement if and when appropriate.”

Acerta specializes in covalent binding technology and is applying this technology to create selective therapies intended for the treatment of cancer and autoimmune diseases. Acerta's lead molecule, acalabrutinib (ACP-196), is a selective and potent inhibitor of Bruton's tyrosine kinase. Acerta is also developing ACP-319, a selective inhibitor of PI3k delta. Acerta is currently developing acalabrutinib in multiple hematologic malignancies and solid tumors, as well as rheumatoid arthritis. A total of 21 clinical trials are currently open and evaluating acalabrutinib alone and in combination with multiple other agents, including pembrolizumab, obinutuzumab, and ACP-319.

Acerta has operations in Oss, the Netherlands and multiple US sites. The US headquarters is in Redwood City, California.

Source: AstraZeneca and Acerta Pharma